Metavention
Manufacturing · Minnesota, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10900 73rd Ave N Ste 101, Maple Grove, M...Phone Number
(612) 814-8200Website
www.metavention.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Metavention
Metavention is focused on innovating treatments for high blood pressure through a unique renal denervation procedure that targets overactive sympathetic nerves. Their iRF Denervation System utilizes radio frequency energy to disrupt these nerves, potentially leading to reduced blood pressure and improvements in metabolic diseases. The company is committed to conducting clinical studies to evaluate the safety and benefits of their treatment. With a patient-centered approach, Metavention aims to deliver life-changing therapies to patients and healthcare providers globally.Explore more
Metavention Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Metavention your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Metavention is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Metavention
Earning: See what the market has to say on Metavention recently announced quarterly report
Funding: Get notified immidiatlly once Metavention has new funding data
Product Launch: Get notified when Metavention launches new products
Check if Metavention has recently received funding, and reach out quickly before it becomes old news!
Metavention, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Metavention had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Metavention as Masked Content
Find 3 more new buyers
Compare Similar Companies to Metavention
Compare insights from companies similar to Metavention, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Metavention is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Metavention is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Metavention.
Metavention financials insights
Gather financial insights about Metavention, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series B
$12M
2017
Series C
$30M
Metavention Tech Stack
A closer look at the technologies used by Metavention
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Left Company
Executive Move
Todd Berg, Chief Executive Officer has assumed the responsibilities of Kevin Hykes, who recently left the organization.
Executive Moves, Left Company
Funding
Funding
Metavention News & Media
Metavention Completes U.S. Enrollment in Groundbreaking Feasibility Study to Treat Type 2 Diabetes
MINNEAPOLIS, Jan. 5, 2022 /PRNewswire/ -- Metavention, Inc. announces the completion of enrollment in the DeLIVER U.S. Study (NCT04285554), to evaluate the safety of sympathetic denervation of the liver using its new Integrated Radio Frequency (iRF) Denervation System. The purpose of the DeLIVER U.S. Study is to establish the safety of liver denervation with the iRF System in patients with a clustering of metabolic diseases, including type 2 diabetes and hypertension, collectively termed as metaMetavention Announces Initiation of Groundbreaking Multi-Organ Denervation Study
MINNEAPOLIS, May 3, 2021 /PRNewswire/ -- Metavention, Inc. announces the initiation of the MODUS Study (ACTRN12620000412932), to treat patients with both type 2 diabetes and hypertension using a catheter-based, minimally invasive approach. The first procedures in this study were...Metavention Closes $65M in Series C Funding
Metavention, Inc., a Minneapolis, CA-based medical device company, completed a $65m Series C financing. The round was led by New Enterprise Associates (NEA) with participation from new investors Sanderling Ventures, RK Mellon and Horowitz Group, plus existing investor Versant Ventures and a corporate investor. The company will use the funds to optimize its novel transcatheter […]Metavention, Inc., Closes $65 Million in Series C Funding, Appoints New Chief Executive Officer
MINNEAPOLIS--(BUSINESS WIRE)--Metavention, Inc., today announced the completion of $65 million in Series C financing. The financing was led by New Enterprise Associates (NEA) and included participation from new investors Sanderling Ventures, RK Mellon and Horowitz Group, plus existing investors Versant Ventures and a corporate investor. Metavention will use the funds to optimize its novel transcatheter based Metabolic Neuromodulation Therapy (MNT) for glucose control in patients with Type 2 dia
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Metavention
Sign Up For FreeTo access detailed company insights
Metavention is focused on innovating treatments for high blood pressure through a unique renal denervation procedure that targets overactive sympathetic nerves. Their iRF Denervation System utilizes radio frequency energy to disrupt these nerves, potentially leading to reduced blood pressure and improvements in metabolic diseases. The company is co... Read More
